Page last updated: 2024-09-03

gefitinib and Day Blindness

gefitinib has been researched along with Day Blindness in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bristow, E; Esmaeli, B; Faulkner, K; Forsythe, BJ; Murray, PI; Tullo, AB	1

Trials

1 trial(s) available for gefitinib and Day Blindness

Article	Year
Ocular findings in patients with solid tumours treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Phase I and II clinical trials. Eye (London, England), 2005, Volume: 19, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Monitoring; ErbB Receptors; Eye Diseases; Female; Gefitinib; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Vision Disorders	2005

Article

Year

Ocular findings in patients with solid tumours treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Phase I and II clinical trials.

Eye (London, England), 2005, Volume: 19, Issue:7

Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Monitoring; ErbB Receptors; Eye Diseases; Female; Gefitinib; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Vision Disorders

2005